share_log

United States Cellular Analyst Ratings

United States Cellular Analyst Ratings

美國蜂窩分析師評級
Benzinga ·  2023/07/26 11:26
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/26/2023 45.79% Morgan Stanley $26 → $27 Maintains Equal-Weight
07/25/2023 45.79% Morgan Stanley $26 → $27 Maintains Equal-Weight
05/08/2023 -13.61% Wells Fargo $22 → $16 Maintains Underweight
02/07/2023 29.59% Morgan Stanley $37 → $24 Maintains Equal-Weight
01/10/2023 7.99% Wells Fargo $33 → $20 Downgrades Overweight → Underweight
11/08/2022 29.59% JP Morgan $32 → $24 Upgrades Underweight → Neutral
11/07/2022 Raymond James Downgrades Strong Buy → Market Perform
08/08/2022 110.58% Raymond James $41 → $39 Maintains Strong Buy
05/09/2022 121.38% Raymond James $40 → $41 Maintains Strong Buy
04/19/2022 99.78% Morgan Stanley → $37 Downgrades Overweight → Equal-Weight
02/22/2022 78.19% Wells Fargo $36 → $33 Maintains Overweight
02/22/2022 115.98% Raymond James $43 → $40 Maintains Strong Buy
08/02/2021 94.38% JP Morgan $35 → $36 Downgrades Neutral → Underweight
07/22/2021 169.98% Morgan Stanley $50.5 → $50 Maintains Overweight
02/22/2021 88.98% JP Morgan $42 → $35 Downgrades Overweight → Neutral
01/14/2021 172.68% Morgan Stanley $57 → $50.5 Maintains Overweight
11/16/2020 94.38% Wells Fargo → $36 Reinstates → Overweight
08/31/2020 148.38% Citigroup $45 → $46 Maintains Buy
08/27/2020 207.78% Morgan Stanley $56 → $57 Maintains Overweight
08/10/2020 132.18% Raymond James $40 → $43 Maintains Strong Buy
07/08/2020 202.38% Morgan Stanley $57 → $56 Maintains Overweight
05/18/2020 115.98% Raymond James $39 → $40 Reiterates → Strong Buy
05/14/2020 83.59% B. Riley Securities $42 → $34 Maintains Neutral
04/22/2020 110.58% Raymond James $41 → $39 Maintains Strong Buy
04/09/2020 207.78% Morgan Stanley $63 → $57 Maintains Overweight
03/27/2020 126.78% JP Morgan $45 → $42 Maintains Overweight
03/02/2020 240.17% Citigroup $66 → $63 Maintains Buy
11/04/2019 164.58% Raymond James $53 → $49 Upgrades Outperform → Strong Buy
11/04/2019 142.98% JP Morgan → $45 Upgrades Neutral → Overweight
08/06/2019 115.98% Wells Fargo $50 → $40 Maintains Market Perform
08/06/2019 126.78% B. Riley Securities $50 → $42 Maintains Neutral
08/05/2019 148.38% JP Morgan → $46 Upgrades Underweight → Neutral
06/18/2019 248.27% Morgan Stanley $44 → $64.5 Upgrades Equal-Weight → Overweight
05/06/2019 186.18% Raymond James $56 → $53 Reiterates → Outperform
11/06/2018 202.38% Raymond James $43 → $56 Maintains Outperform
08/08/2018 175.38% Citigroup $49 → $51 Maintains Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
07/26/2023 45.79% 摩根士丹利 $26→$27 維護 等重
07/25/2023 45.79% 摩根士丹利 $26→$27 維護 等重
05/08/2023 -13.61% 富國銀行 $22→$16 維護 體重不足
02/07/2023 29.59% 摩根士丹利 $37→$24 維護 等重
2023年1月10日 7.99% 富國銀行 $33→$20 評級下調 增持→減持
11/08/2022 29.59% 摩根大通 $32→$24 升級 減重→中性
11/07/2022 - 雷蒙德·詹姆斯 評級下調 強勁的購買→市場表現
2022/08/08 110.58% 雷蒙德·詹姆斯 $41→$39 維護 強勢購買
05/09/2022 121.38% 雷蒙德·詹姆斯 $40→$41 維護 強勢購買
04/19/2022 99.78% 摩根士丹利 →$37 評級下調 超重→等重
02/22/2022 78.19% 富國銀行 $36→$33 維護 超重
02/22/2022 115.98% 雷蒙德·詹姆斯 $43→$40 維護 強勢購買
08/02/2021 94.38% 摩根大通 $35→$36 評級下調 中性→減持
07/22/2021 169.98% 摩根士丹利 $50.5→$50 維護 超重
02/22/2021 88.98% 摩根大通 $42→$35 評級下調 超重→中性
2021/01/14 172.68% 摩根士丹利 $57→$50.5 維護 超重
11/16/2020 94.38% 富國銀行 →$36 恢復 →超重
08/31/2020 148.38% 花旗集團 $45→$46 維護
2020/08/27 207.78% 摩根士丹利 $56→$57 維護 超重
2020/08/10 132.18% 雷蒙德·詹姆斯 $40→$43 維護 強勢購買
07/08/2020 202.38% 摩根士丹利 $57→$56 維護 超重
05/18/2020 115.98% 雷蒙德·詹姆斯 $39→$40 重申 →強勢購買
2020/05/14 83.59% B.萊利證券 $42→$34 維護 中性
04/22/2020 110.58% 雷蒙德·詹姆斯 $41→$39 維護 強勢購買
04/09/2020 207.78% 摩根士丹利 $63→$57 維護 超重
03/27/2020 126.78% 摩根大通 $45→$42 維護 超重
03/02/2020 240.17% 花旗集團 $66→$63 維護
2019/11/04 164.58% 雷蒙德·詹姆斯 $53→$49 升級 跑贏→強勢買入
2019/11/04 142.98% 摩根大通 →$45 升級 中性→超重
2019年08月06日 115.98% 富國銀行 $50→$40 維護 市場表現
2019年08月06日 126.78% B.萊利證券 $50→$42 維護 中性
2019年08月05日 148.38% 摩根大通 →$46 升級 減重→中性
2019年06月18日 248.27% 摩根士丹利 $44→$64.5 升級 等重→超重
2019年05月06日 186.18% 雷蒙德·詹姆斯 $56→$53 重申 →跑贏大盤
2018/06/11 202.38% 雷蒙德·詹姆斯 $43→$56 維護 跑贏大盤
2018/08/08 175.38% 花旗集團 $49→$51 維護

What is the target price for United States Cellular (USM)?

美國蜂窩(USM)的目標價是多少?

The latest price target for United States Cellular (NYSE: USM) was reported by Morgan Stanley on July 26, 2023. The analyst firm set a price target for $27.00 expecting USM to rise to within 12 months (a possible 45.79% upside). 8 analyst firms have reported ratings in the last year.

美國蜂窩(紐約證券交易所代碼:USM)的最新目標價是由摩根士丹利於2023年7月26日報道的。這家分析公司將目標價定為27美元,預計USM將在12個月內上漲至45.79%(可能上漲45.79%)。去年有8家分析公司公佈了評級。

What is the most recent analyst rating for United States Cellular (USM)?

美國蜂窩(USM)的最新分析師評級是多少?

The latest analyst rating for United States Cellular (NYSE: USM) was provided by Morgan Stanley, and United States Cellular maintained their equal-weight rating.

美國蜂窩公司(紐約證券交易所代碼:USM)的最新分析師評級由摩根士丹利提供,美國蜂窩公司維持其同等權重評級。

When is the next analyst rating going to be posted or updated for United States Cellular (USM)?

美國蜂窩(USM)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United States Cellular, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United States Cellular was filed on July 26, 2023 so you should expect the next rating to be made available sometime around July 26, 2024.

分析師在進行了廣泛的研究後得出了股票評級,這些研究包括查閱公共財務報表,與United States Ccell的高管和客戶交談,以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。美國蜂窩的上一次評級是在2023年7月26日提交的,所以你應該預計下一次評級將在2024年7月26日左右的某個時候提供。

Is the Analyst Rating United States Cellular (USM) correct?

分析師對美國蜂窩(USM)的評級正確嗎?

While ratings are subjective and will change, the latest United States Cellular (USM) rating was a maintained with a price target of $26.00 to $27.00. The current price United States Cellular (USM) is trading at is $18.52, which is out of the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的美國蜂窩(USM)評級維持不變,目標價在26.00美元至27.00美元之間。目前美國移動(USM)的交易價格為18.52美元,超出了分析師的預測範圍。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論